Cancer Statistics, 1988

Silverberg, Edwin; Lubera, John A.

doi:10.3322/canjclin.38.1.5

Cited by 185 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…About 20-40% of whole cancer patients are estimated to develop brain metastasis and the most common primary sites are lung, breast, and gastrointestinal cancer [1,2]. Reportedly, when brain metastases were first diagnosed in the solid tumor patients, single metastasis were 37-50%, and multiple were 50-63% [3-5].…”

Section: Introductionmentioning

confidence: 99%

Clinical application of RapidArc volumetric modulated arc therapy as a component in whole brain radiation therapy for poor prognostic, four or more multiple brain metastases

Lee

Choi

et al. 2012

Radiat Oncol J

View full text Add to dashboard Cite

PurposeTo determine feasibility of RapidArc in sequential or simultaneous integrated tumor boost in whole brain radiation therapy (WBRT) for poor prognostic patients with four or more brain metastases.Materials and MethodsNine patients with multiple (≥4) brain metastases were analyzed. Three patients were classified as class II in recursive partitioning analysis and 6 were class III. The class III patients presented with hemiparesis, cognitive deficit, or apraxia. The ratio of tumor to whole brain volume was 0.8-7.9%. Six patients received 2-dimensional bilateral WBRT, (30 Gy/10-12 fractions), followed by sequential RapidArc tumor boost (15-30 Gy/4-10 fractions). Three patients received RapidArc WBRT with simultaneous integrated boost to tumors (48-50 Gy) in 10-20 fractions.ResultsThe median biologically effective dose to metastatic tumors was 68.1 Gy10 and 67.2 Gy10 and the median brain volume irradiated more than 100 Gy3 were 1.9% (24 cm3) and 0.8% (13 cm3) for each group. With less than 3 minutes of treatment time, RapidArc was easily applied to the patients with poor performance status. The follow-up period was 0.3-16.5 months. Tumor responses among the 6 patients who underwent follow-up magnetic resonance imaging were partial and stable in 3 and 3, respectively. Overall survival at 6 and 12 months were 66.7% and 41.7%, respectively. The local progression-free survival at 6 and 12 months were 100% and 62.5%, respectively.ConclusionRapidArc as a component in whole brain radiation therapy for poor prognostic, multiple brain metastases is an effective and safe modality with easy application.

show abstract

Section: Introductionmentioning

confidence: 99%

Clinical application of RapidArc volumetric modulated arc therapy as a component in whole brain radiation therapy for poor prognostic, four or more multiple brain metastases

Lee

Choi

et al. 2012

Radiat Oncol J

View full text Add to dashboard Cite

show abstract

“…In fact, over 50% of lung cancer patients are diagnosed at age older than 65 years and around 30% are diagnosed at age beyond 70 years[34],[35]. Generally speaking, ageing is associated with not only significant physiological changes (functional status, organ function, and drug pharmacokinetics, etc.…”

Section: Discussionmentioning

confidence: 99%

Weekly intravenous nanoparticle albumin-bound paclitaxel for elderly patients with stage IV non-small-cell lung cancer: a series of 20 cases

2012

View full text Add to dashboard Cite

The purpose of this study was to evaluate the efficacy and safety of nanoparticle albumin-bound paclitaxel as a rescue regimen in the treatment of patients with advanced non-small-cell lung cancer. We retrospectively reviewed the medical records of 20 patients with stage IV non-small-cell lung cancer. The patients had progressive disease after standard antitumor therapy and subsequently received intravenous albumin-bound paclitaxel at the dose of 100 mg/m2 in weekly schedule. Cumulative findings showed that the overall response rate was 30.0%, the disease control rate amounted to 40%, and the 1 year survival rate was 30%. In addition, the median time to progression and the median survival time reached 5 and 10 months, respectively. Meanwhile, no severe hypersensitivity reactions and grade 4 adverse effects were reported. In summary, weekly-administered albumin-bound paclitaxel seems to be an effective and safe regimen for elderly patients with stage IV non-small-cell lung cancer who were refractory to conventional therapy.

show abstract

“…In the USA, 47% of all patients with non-small cell lung cancer (NSCLC) are in the age group of 70 years and older. Of 1,200,000 patients with NSCLC worldwide, 300,000 are over 70 years of age [ 2 , 3 ]. Multi-organ failure, multiple drug use, and a decrease in the functional reserve of organs such as bone marrow are seen with aging.…”

Section: Introductionmentioning

confidence: 99%

Treatment Approaches in 102 Elderly Patients With Non-Small Cell Lung Cancer

et al. 2015

View full text Add to dashboard Cite

BackgroundThe life expectancy and presence of co-morbidities cause reservations in treatment decisions for elderly patients with cancer. In this study, we retrospectively evaluated 102 patients who are considered as middle-old aged (aged 75 - 84) by gerontologists.MethodsMedical records of patients were reviewed. One hundred and two patients with a diagnosis of non-small cell lung cancer (NSCLC) whose follow-up ended with death between March 2006 and May 2013 were examined.ResultsThe median age at diagnosis was 77 (75 - 85) years. Thirty-three patients (67.6%) were over 80 years old. The number of patients with metastasis was 57 (55.8%). Forty-two (41.2%) patients had stage IIIA and IIIB disease. Fifteen of the metastatic patients (26.3%) were given chemotherapy, while 12 of the non-metastatic patients (26.6%) were given chemotherapy. Of the non-metastatic patients, 25 (55.6%) were treated with radiotherapy, and five (11.1%) were treated with chemotherapy. The median duration of follow-up was 4 (1-55) months. Progression-free survival (PFS) was 4 months in non-metastatic patients, and 3 months in metastatic patients. Overall survival (OS) was 4 months. OS rates for 1 and 2 years were 10% and 2%.ConclusionChemotherapy and radiotherapy may be administered even to patients of this age group. The beneficial effect of chemotherapy in patients with metastasis on OS is an important finding of our study.

show abstract

Cancer Statistics, 1988

Cited by 185 publications

References 0 publications

Clinical application of RapidArc volumetric modulated arc therapy as a component in whole brain radiation therapy for poor prognostic, four or more multiple brain metastases

Clinical application of RapidArc volumetric modulated arc therapy as a component in whole brain radiation therapy for poor prognostic, four or more multiple brain metastases

Weekly intravenous nanoparticle albumin-bound paclitaxel for elderly patients with stage IV non-small-cell lung cancer: a series of 20 cases

Treatment Approaches in 102 Elderly Patients With Non-Small Cell Lung Cancer

Contact Info

Product

Resources

About